Western Securities: First giving a "Buy" rating to WuXi AppTec (02268.HK) with rapid growth in project numbers and outstanding orders.

The Wisdom Finance APP learned that West Securities released a research report covering Pharmaron (02268.HK) for the first time, giving it a "buy" rating. It is expected that the company's revenue will be 6.001/8.113/10.736 billion RMB respectively from 2025 to 2027, with year-on-year growth rates of 48.1%/35.2%/32.3%, and the net profit attributable to the parent company will be 1.607/2.171/2.910 billion RMB, with year-on-year growth rates of 50.3%/35.1%/34.1%.